Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024
| LRMR Stock | USD 6.07 0.13 2.10% |
Slightly above 56% of all Larimar Therapeutics' retail investors are looking to take a long position. The analysis of the overall investor sentiment regarding Larimar Therapeutics suggests that some traders are interested. Larimar Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Larimar Therapeutics. Many technical investors use Larimar Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Larimar |
Treatment with nomlabofusp modified gene expression and lipid profiles in addition to increasing frataxin levels in study participants with Friedreichs ataxia Modeling and simulation predict that, in most patients with FA, 50 mg of nomlabofusp administered daily is likely to achieve FXN levels that are 50 percent of levels observed in healthy controls and similar to mean FXN levels reported in asymptomatic heterozygous carriers Disease characteristics of adult participants in the nomlabofus
Read at finance.yahoo.com
 |
Larimar Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Larimar Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Larimar Therapeutics Fundamental Analysis
We analyze Larimar Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Larimar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Larimar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Larimar Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Larimar Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Larimar Therapeutics stock to make a market-neutral strategy. Peer analysis of Larimar Therapeutics could also be used in its relative valuation, which is a method of valuing Larimar Therapeutics by comparing valuation metrics with similar companies.
Peers
Larimar Therapeutics Related Equities
| CHRS | Coherus BioSciences | 24.82 | ||||
| KROS | Keros Therapeutics | 9.78 | ||||
| SPRO | Spero Therapeutics | 2.65 | ||||
| CNTA | Centessa Pharmaceuticals | 1.00 | ||||
| SRZN | Surrozen | 0.70 | ||||
| ALEC | Alector | 0.40 | ||||
| STRO | Sutro Biopharma | 0.36 | ||||
| SNDX | Syndax Pharmaceuticals | 0.48 | ||||
| IKNA | Ikena Oncology | 0.58 | ||||
| CELC | Celcuity LLC | 0.71 | ||||
| IMRX | Immuneering Corp | 0.95 | ||||
| PCVX | Vaxcyte | 1.34 | ||||
| BOLT | Bolt Biotherapeutics | 1.56 | ||||
| DAWN | Day One | 1.81 | ||||
| KZR | Kezar Life | 4.59 | ||||
| MRUS | Merus BV | 4.78 | ||||
| CABA | Cabaletta Bio | 13.80 |
Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.